Dyne Therapeutics (DYN) Invested Capital (2020 - 2026)
Dyne Therapeutics (DYN) posted quarterly Invested Capital of $200.0 million for Q2 2026, up 100.0% year-over-year from $100.0 million in Q2 2025, and up 33.33% quarter-over-quarter from $150.0 million in Q1 2026.
Powered by 
Analysis
Dyne Therapeutics (DYN) Invested Capital (2020 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Invested Capital for 2 consecutive years, with $200.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Invested Capital rose 100.0% year-over-year to $200.0 million; the TTM figure through Jun 2026 stood at $517.1 million (up 417.13% YoY), while the FY2025 annual figure was $67.1 million, changed N/A from the prior year.
- Invested Capital advanced to $200.0 million in Q2 2026 per DYN's latest filing, from $150.0 million in the prior quarter.
- Across five years, Invested Capital topped out at $200.0 million in Q2 2026 and bottomed at $67.1 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 33.70 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7.35 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 6.25 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.13 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.30 Bn |
| 10 | Dyne Therapeutics | 4.02 Bn | 4.02 Bn | - | 901.48 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 901.48 Mn |
| Mar 31, 2026 | 1.01 Bn |
| Dec 31, 2025 | 1.19 Bn |
| Sep 30, 2025 | 790.93 Mn |
| Jun 30, 2025 | 670.26 Mn |
| Dec 31, 2024 | 629.84 Mn |
| Sep 30, 2020 | 376.78 Mn |